6533b870fe1ef96bd12cfb58

RESEARCH PRODUCT

Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age

Matthew D. SnapeMerryn VoyseyAdam FinnGianni BonaSusanna EspositoNicola PrincipiJavier Diez-domingoEtienne SokalDorothee KieningerRoman PrymulaPeter M DullIgor KohlMichelangelo BaroneHuajun WangDaniela ToneattoAndrew J PollardEuropean Menb Vaccine Study Group

subject

MaleMicrobiology (medical)Pediatricsmedicine.medical_specialtypaediatricpersistence of immunityImmunization SecondaryMeningococcal VaccinesMeningococcal vaccineBooster doseMeningitis MeningococcalNeisseria meningitidis Serogroup BPaediatric; Persistence of immunity; Serogroup B meningococcal vaccine; Serum bactericidal activity;Serum bactericidal activityserum bactericidal activity03 medical and health sciences0302 clinical medicine030225 pediatricsOutcome Assessment Health CaremedicineHumansmedia_common.cataloged_instance030212 general & internal medicineToddlerEuropean unionSerogroup B meningococcal vaccineImmunization Schedulemedia_commonMedicine(all)MeningococcalBooster (rocketry)business.industryVaccinationInfantbactericidal antibodiesmedicine.diseaseAntibodies BacterialEuropeVaccinationInfectious DiseasesImmunizationPaediatricChild PreschoolPediatrics Perinatology and Child HealthPersistence of immunityFemaleImmunizationbusinessMeningitis

description

Background: A serogroup B meningococcal vaccine (4CMenB) is licensed for infant use in countries including Canada, Australia and those of the European Union. Data on serum bactericidal antibody (hSBA) waning and the ideal timing of a "toddler" booster dose are essential to optimize vaccine utilization. Methods: An open-labeled, multicenter phase-2b follow-on European study conducted from 2009 to 2012. Participants previously receiving 4CMenB with routine vaccines at 2, 4 and 6 or 2, 3 and 4 months (246Con and 234Con) or at 2, 4 and 6 months intercalated with routine vaccines (246Int) received a booster dose at 12, 18 or 24 months. 4CMenB-naive "Control" participants aged 12, 18 or 24 months received 2 doses of 4CMenB 2 months apart. Results: One thousand five hundred eighty-eight participants were recruited. At 12 months, before any booster doses, the proportions with hSBA titers >= 1:5 for strain 44/76-SL (testing vaccine component fHBP) were 73% (120/165) for the "246Con" group, 85% (125/147) for "246Int," 57% (51/90) for "234Con" and 13% (26/199) for Controls. For strain 5/99 (NadA) proportions were >= 96% (all 4CMenB-recipients) and 1% (Controls). For strain NZ98/254 (PorA), these were 18-35% (4CMenB-recipients) and 1% (Controls). By 24 months, 4CMenB-recipient proportions were 13-22% (44/76-SL), 82-94% (5/99) and 7-13% (NZ98/254) and in controls = 95% of previously immunized participants had titers >= 1:5 (all strains). Conclusions: A 4CMenB booster-dose can overcome waning hSBA titers after early-infant immunization. Administration at 12 months could help to maintain immunity during an age of high risk, and the persistence of this response requires further study.

yearjournalcountryeditionlanguage
2016-04-01Pediatric Infectious Disease Journal
https://doi.org/10.1097/inf.0000000000001056